FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983294552> ?p ?o ?g. }

• W1983294552 endingPage "8" @default.
• W1983294552 startingPage "5" @default.
• W1983294552 abstract "Future CardiologyVol. 4, No. 1 EditorialFree AccessUnderstanding how statins work: the path to better treatments for heart disease and moreJohn S Hill & Guosong QiuJohn S Hill† Author for correspondenceAtherosclerosis Specialty Laboratory, Healthy Heart Program, St Paul’s Hospital, James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. Search for more papers by this authorEmail the corresponding author at jshill@interchange.ubc.ca & Guosong QiuAtherosclerosis Specialty Laboratory, Healthy Heart Program, St Paul’s Hospital, James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. Search for more papers by this authorEmail the corresponding author at gsqiu@panagin.comPublished Online:18 Dec 2007https://doi.org/10.2217/14796678.4.1.5AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail The increasing use of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors (statins) has revealed beneficial effects that are independent of their intended lipid-lowering effects. Understanding the mechanisms of how statins facilitate these effects may help extend their indications in both cardiovascular and noncardiovascular diseases and perhaps lead to the development of additional novel pharmaceuticals.Owing to their structural similarity with HMG-CoA, statins are able to competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. The consequence of this inhibition is a reduction in cholesterol synthesis and subsequent secretion of ApoB-containing lipoproteins and an increase in the clearance of LDL-cholesterol through the upregulation of the LDL receptor. A variety of clinical studies have demonstrated the efficacy of statins in LDL-cholesterol lowering, a reduction that is approximately two-to-four-times as effective as observed with fibrate treatment. In general, statin treatment achieves 80–100% success for a 30% reduction in LDL-cholesterol in primary prevention, which corresponds to an approximately 30% reduction in cardiovascular events, including acute coronary syndrome (ACS), myocardial infarction and stroke for secondary prevention [1–5].Nonlipid-lowering effects of statinsSeveral clinical trials including Heart Protection Study (HPS), Collaborative Atorvastatin Diabetes Study (CARDS) and Treating to New Targets (TNT) Study have suggested that statins can offer protection to patients with normal lipid levels through various nonlipid-lowering effects. For example, statins can upregulate or recover nitric oxide synthase expression in endothelia, not only in the absence of risk factors, but also when treated with oxidized LDL (OxLDL), TNF-α and during hypoxic conditions. Clinically, statins have been shown to restore endothelial function, improve flow-mediated dilation and blood flow of the brachial artery within 24 h, independent of changes in LDL [6].Statins also have inherent anti-inflammatory abilities, as treatment can reduce the expression of adhesion molecules and chemokines such as ICAM-1, integrin adhesion molecules, MCP-1, IL-8, CX3CL1 and CX3CR1, and thereby decrease subsequent inflammatory cell adhesion to endothelia and production of proinflammatory cytokines [7]. C-reactive protein (CRP), a well-recognized inflammatory biomarker, is also reduced by statins in human hepatocytes, leading to a lower CRP level as reported in the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT-TIMI 22) trial [8–10].Oxidative stress can also be ameliorated with statin therapy. Statins negatively regulate the formation of the NAD(P)H oxidase subunit p22phox- and myeloperoxidase-derived reactive oxygen species [11,12]. Furthermore, statins strengthen systemic antioxidant effects through the upregulation of heme oxygenase-1, catalase, superoxide dismutase, glutathione peroxidase and paraoxonase 1 expression in a variety of cells, promoting protection against oxidative stress [13]. Coincident with decreased plasma endogenous peroxide concentrations and increased total antioxidant capacity, antibody titers to malondialdehyde-LDL, Cu-OxLDL and OxLDL are also decreased in patients receiving statin therapy [14].Statins have also been reported to stabilize atherosclerotic plaques and may, in fact, cause their regression. Matrix metalloproteinase production, which has been related to the thinning of the fibrous cap and plaque rupture, can be effectively suppressed by statins in macrophages and smooth muscle cells [15]. In addition, statin therapy represses plaque neovascularization and the COX-2/microsomal prostaglandin E synthase-1 proinflammatory pathway, which favor plaque destabilization. Statins are also well-known, potent inhibitors of smooth muscle cell migration and proliferation, and sensitize human smooth muscle cells to undergo apoptosis. High-dose statin therapy has been demonstrated to stop or even regress plaque progression as reported in the Reversing Atherosclerosis with Aggressive Lipid Lowering (REVERSAL), Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin (METEOR) and A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) studies [16–18].Many studies have provided evidence that statins can effectively interfere with thrombosis through:• Inactivation of coagulation• Platelet inactivation• Fibrinolytic activationIn coronary artery disease patients, statins slow blood clotting corresponding to decreased thrombin formation and attenuated coagulation factor activation [19]. Furthermore, statins inhibit the activity and antigen level of the platelet proteinase-activated receptor-1 thrombin receptor, CD40L, von Willebrand factor and tissue factors, resulting in reduced platelet aggregability. Finally, statin treatment drives the fibrinolytic process by upregulating tissue plasminogen activator and downregulating plasminogen activator inhibitor-1 [20], so as to remove fibrin from injured endothelial surfaces and eliminating the nidus for platelet aggregation and the cascade effect of the thrombotic response.The immunomodulatory properties of statins is the focus of recent research. Statins particularly affect monocyte functions by blunting the expression of Toll-like receptor 4 and 2 [21,22]. The activation of T lymphocytes, natural killer cells and dendritic cells, and the subsequent production of lymphokines are also attenuated by statin treatment. In addition, statins promote T helper cell (Th)2 polarization through both the inhibition of the IFN-γ-producing Th1 response and augmentation of the Th2 development of CD4+ T cells [23]. Furthermore, the expression of MHC-II molecules in macrophages and endothelial cells, which are directly involved in antigen presenting and T-lymphocyte activation, is also effectively suppressed by statins [24]. In addition, reduced cell-surface expression of other immunoregulatory molecules, including MHC-I, CD3, -4, -8, -28, -40, -80, -86 and -54 by statins influences lymphocyte homing and the subsequent immune response [25].How do statins exert nonlipid-lowering effects?Statin treatment reduces the production of intermediates for cholesterol synthesis, especially isoprenoids such as farnesylpyrophosphate and geranylgeranylpyrophosphate. These intermediates can influence many intracellular signaling pathways through the prenylation of small G proteins. Thus far, small G proteins have been found to be involved in the regulation of MAPKs (ERK, c-Jun N-terminal kinase, P38 MAPK), PI3K-Akt and protein kinase C-nuclear factor-κB pathways.Two important intranuclear receptor pathways for the pathognesis of cardiovascular diseases, namely liver X receptors (LXRs) and PPARs are additional targets of statin treatment. Cholesterol derivatives such as oxysterols are recognized ligands for LXRs. The reduction of oxysterols consequent to statin therapy is accompanied by the corresponding inactivation of LXRs, causing altered expression of downstream genes such as lipases [26]. Statin treatment is also able to activate PPAR-α and -γ. The mechanism by which statins activate PPARs, however, remains unclear.New applications of statinsRecently, new applications of statins in cardiovascular disease, such as ischemia-reperfusion injury, heart failure (HF) and arrhythmia have been documented in several clinical trials. In Aggrastat to Zocor (A to Z), Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes (MIRACL) and PROVE IT-TIMI 22 trials, the early initiation of an aggressive statin regimen within 24–96 h among patients with ACS resulted in reduced myocardial ischemia-reperfusion injury and a favorable reduction in major cardiovascular events. However, delayed initiation of statin therapy, even within 14 days after ACS, did not confer benefits up to 4 months.Statin administration is also associated with improved cardiac function and reduced arrhythmia episodes in both ischemic and nonischemic diseases. This treatment reduces the rate of hospitalization for HF by 27% [27]. In patients with dilated cardiomyopathy or implantable cardioverter defibrillator implantation, statins reduce the risk of arrhythmias (particularly malignant ventricular arrhythmia). Furthermore, pre- or concomitant treatment with statins significantly reduces the incidence of atrial fibrillation after acute elective cardiac surgery [28,29].Statins may also deliver beneficial effects on restenosis prevention after percutaneous coronary intervention and aortic stenosis, for which large-scaled studies are underway [30,31]. Moreover, the immunomodulatory property of statins can potentially ameliorate cardiac allograft rejection, resulting in improved survival and a significantly lower incidence of transplant vasculopathy [32]. Immunomodulation by statins may also influence the course of immune-related diseases, such as Alzheimer’s disease/dementia, multiple sclerosis, inflammatory bowel diseases, rheumatic arthritis and ankylosing spondylitis. However, at present, no definitive conclusions can be drawn until large-scale clinical trials have been completed.Future perspectiveThere is abundant evidence to suggest that statins have a variety of influences beyond their initially intended lipid-lowering effects. There is great value in elucidating the specific mechanisms of these effects as it is this knowledge that should guide the application of this class of drugs in patients in different clinical settings. The lack of adverse side effects for this class of compounds also makes it an attractive adjunctive therapy in specific applications. The future appears bright for statin therapy as its applications and benefits continue to multiply.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.Bibliography1 Pedersen TR, Kjekshus J, Berg K et al.: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler. Suppl.344(8934),1383–1389 (1994).Google Scholar2 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N. Engl. J. Med.339(19),1349–1357 (1998).Crossref, Medline, Google Scholar3 Downs JR, Clearfield M, Weis S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA279(20),1615–1622 (1998).Crossref, Medline, CAS, Google Scholar4 Shepherd J, Blauw GJ, Murphy MB et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360(9346),1623–1630 (2002).Crossref, Medline, CAS, Google Scholar5 Shepherd J, Cobbe SM, Ford I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333(20),1301–1307 (1995).Crossref, Medline, CAS, Google Scholar6 Beckman JA, Liao JK, Hurley S et al.: Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ. Res.95(2),217–223 (2004).Crossref, Medline, CAS, Google Scholar7 Forrester JS, Libby P: The inflammation hypothesis and its potential relevance to statin therapy. Am. J. Cardiol.99(5),732–738 (2007).Crossref, Medline, CAS, Google Scholar8 Arnaud C, Burger F, Steffens S et al.: Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler. Thromb. Vasc. Biol.25(6),1231–1236 (2005).Crossref, Medline, CAS, Google Scholar9 Mayer C, Gruber HJ, Landl EM et al.: Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int. J. Clin. Pharmacol. Ther.45(6),319–327 (2007).Crossref, Medline, CAS, Google Scholar10 Ray KK, Cannon CP, Cairns R et al.: Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol.46(8),1417–1424 (2005).Crossref, Medline, CAS, Google Scholar11 Rueckschloss U, Galle J, Holtz J et al.: Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation104(15),1767–1772 (2001).Crossref, Medline, CAS, Google Scholar12 Kumar AP, Reynolds WF: Statins downregulate myeloperoxidase gene expression in macrophages. Biochem. Biophys. Res. Commun.331(2),442–451 (2005).Crossref, Medline, CAS, Google Scholar13 Davignon J, Jacob RF, Mason RP: The antioxidant effects of statins. Coron. Artery. Dis.15(5),251–258 (2004)Crossref, Medline, Google Scholar14 Resch U, Tatzber F, Budinsky A et al.: Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br. J. Clin. Pharmacol.61(3),262–274 (2006).Crossref, Medline, CAS, Google Scholar15 Luan Z, Chase AJ, Newby AC: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol.23(5),769–775 (2003).Crossref, Medline, CAS, Google Scholar16 Nissen SE, Tuzcu EM, Schoenhagen P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291(9),1071–1080 (2004).Crossref, Medline, CAS, Google Scholar17 Nissen SE, Nicholls SJ, Sipahi I et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295(13),1556–1565 (2006).Crossref, Medline, CAS, Google Scholar18 Crouse JR 3rd, Raichlen JS, Riley WA et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA297(12),1344–1353 (2007).Crossref, Medline, CAS, Google Scholar19 Undas A, Celinska-Lowenhoff M, Brummel-Ziedins KE et al.: Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol.25(7),1524–1525 (2005).Crossref, Medline, CAS, Google Scholar20 Mussoni L, Banfi C, Sironi L et al.: Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb. Haemost.84(1),59–64 (2000)Crossref, Medline, CAS, Google Scholar21 Niessner A, Steiner S, Speidl WS et al.: Simvastatin suppresses endotoxin-induced upregulation of Toll-like receptors 4 and 2 in vivo. Atherosclerosis189(2),408–413 (2006).Crossref, Medline, CAS, Google Scholar22 Methe H, Kim JO, Kofler S et al.: Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler. Thromb. Vasc. Biol.25(7),1439–1445 (2005).Crossref, Medline, CAS, Google Scholar23 Hakamada-Taguchi R, Uehara Y, Kuribayashi K et al.: Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ. Res.93(10),948–956 (2003).Crossref, Medline, CAS, Google Scholar24 Geissler I, Collins L, Schofield R et al.: In vivo suppression of major histocompatibility complex class II expression on porcine vascular endothelial cells by an HMG-CoA reductase inhibitor. Transplantation81(6),922–926 (2006).Crossref, Medline, CAS, Google Scholar25 Kuipers HF, Biesta PJ, Groothuis TA et al.: Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum. Immunol.66(6),653–665 (2005).Crossref, Medline, CAS, Google Scholar26 Qiu G, Hill JS: Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J. Lipid. Res.48(10),2112–2122 (2007).Crossref, Medline, CAS, Google Scholar27 Scirica BM, Morrow DA, Cannon CP et al.: Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol.47(11),2326–2331 (2006).Crossref, Medline, CAS, Google Scholar28 Patti G, Chello M, Candura D et al.: Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation114(14),1455–1461 (2006).Crossref, Medline, CAS, Google Scholar29 Ramani G, Zahid M, Good CB et al.: Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am. J. Cardiol.100(3),404–405 (2007).Crossref, Medline, Google Scholar30 Chan KL, Teo K, Tam J et al.: Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial. Am. Heart. J.153(6),925–931 (2007).Crossref, Medline, CAS, Google Scholar31 Rossebo AB, Pedersen TR, Allen C et al.: Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am. J. Cardiol.99(7),970–973 (2007).Crossref, Medline, CAS, Google Scholar32 Wenke K, Meiser B, Thiery J et al.: Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation107(1),93–97 (2003).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 4, No. 1 Follow us on social media for the latest updates Metrics Downloaded 778 times History Published online 18 December 2007 Published in print January 2008 Information© Future Medicine LtdFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W1983294552 created "2016-06-24" @default.
• W1983294552 creator A5044040895 @default.
• W1983294552 creator A5083520083 @default.
• W1983294552 date "2008-01-01" @default.
• W1983294552 modified "2023-09-23" @default.
• W1983294552 title "Understanding how statins work: the path to better treatments for heart disease and more" @default.
• W1983294552 cites W1478708262 @default.
• W1983294552 cites W193160846 @default.
• W1983294552 cites W1968240228 @default.
• W1983294552 cites W1980051680 @default.
• W1983294552 cites W1996495655 @default.
• W1983294552 cites W2002100924 @default.
• W1983294552 cites W2002240714 @default.
• W1983294552 cites W2005536112 @default.
• W1983294552 cites W2007129673 @default.
• W1983294552 cites W2024815256 @default.
• W1983294552 cites W2031579146 @default.
• W1983294552 cites W2037335513 @default.
• W1983294552 cites W2046478130 @default.
• W1983294552 cites W2052365898 @default.
• W1983294552 cites W2062661553 @default.
• W1983294552 cites W2073252878 @default.
• W1983294552 cites W2089660664 @default.
• W1983294552 cites W2092284960 @default.
• W1983294552 cites W2098576019 @default.
• W1983294552 cites W2121116134 @default.
• W1983294552 cites W2125711853 @default.
• W1983294552 cites W2129750583 @default.
• W1983294552 cites W2135631433 @default.
• W1983294552 cites W2143835519 @default.
• W1983294552 cites W2146228563 @default.
• W1983294552 cites W2155598961 @default.
• W1983294552 cites W2159974155 @default.
• W1983294552 cites W2165405205 @default.
• W1983294552 cites W2166910397 @default.
• W1983294552 cites W2313364580 @default.
• W1983294552 cites W38523360 @default.
• W1983294552 doi "https://doi.org/10.2217/14796678.4.1.5" @default.
• W1983294552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19804266" @default.
• W1983294552 hasPublicationYear "2008" @default.
• W1983294552 type Work @default.
• W1983294552 sameAs 1983294552 @default.
• W1983294552 citedByCount "0" @default.
• W1983294552 crossrefType "journal-article" @default.
• W1983294552 hasAuthorship W1983294552A5044040895 @default.
• W1983294552 hasAuthorship W1983294552A5083520083 @default.
• W1983294552 hasConcept C126322002 @default.
• W1983294552 hasConcept C164705383 @default.
• W1983294552 hasConcept C177713679 @default.
• W1983294552 hasConcept C199360897 @default.
• W1983294552 hasConcept C2777735758 @default.
• W1983294552 hasConcept C2779134260 @default.
• W1983294552 hasConcept C41008148 @default.
• W1983294552 hasConcept C71924100 @default.
• W1983294552 hasConceptScore W1983294552C126322002 @default.
• W1983294552 hasConceptScore W1983294552C164705383 @default.
• W1983294552 hasConceptScore W1983294552C177713679 @default.
• W1983294552 hasConceptScore W1983294552C199360897 @default.
• W1983294552 hasConceptScore W1983294552C2777735758 @default.
• W1983294552 hasConceptScore W1983294552C2779134260 @default.
• W1983294552 hasConceptScore W1983294552C41008148 @default.
• W1983294552 hasConceptScore W1983294552C71924100 @default.
• W1983294552 hasIssue "1" @default.
• W1983294552 hasLocation W19832945521 @default.
• W1983294552 hasLocation W19832945522 @default.
• W1983294552 hasOpenAccess W1983294552 @default.
• W1983294552 hasPrimaryLocation W19832945521 @default.
• W1983294552 hasRelatedWork W2011347913 @default.
• W1983294552 hasRelatedWork W2049397185 @default.
• W1983294552 hasRelatedWork W2073151595 @default.
• W1983294552 hasRelatedWork W2074833529 @default.
• W1983294552 hasRelatedWork W2125804349 @default.
• W1983294552 hasRelatedWork W2159512267 @default.
• W1983294552 hasRelatedWork W2304633692 @default.
• W1983294552 hasRelatedWork W2355498105 @default.
• W1983294552 hasRelatedWork W2399063111 @default.
• W1983294552 hasRelatedWork W2414320482 @default.
• W1983294552 hasVolume "4" @default.
• W1983294552 isParatext "false" @default.
• W1983294552 isRetracted "false" @default.
• W1983294552 magId "1983294552" @default.
• W1983294552 workType "article" @default.